Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) announced its plan to release unaudited financial results for the fourth quarter ended December 31, 2022, on Monday, March 13, 2023, before U.S. markets open. The company, focused on developing affordable cell therapies for cancer treatment, will provide updates on its recent developments during a live audio webcast and conference call at 8:00 a.m. ET. Investors can join the call via domestic dial-in at (800) 715-9871 or international dial-in at (646) 307-1963, using conference ID 5617240. A replay will be accessible on Gracell's investor relations webpage post-event.

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the fourth quarter ended December 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, March 13, 2023. The management team will host a live audio webcast and conference call at 8:00 am Eastern Time.

Conference call and webcast details:

Monday, March 13, 2023 @ 8:00 a.m. ET 
Investor domestic dial-in: (800) 715-9871 
Investor international dial-in: (646) 307-1963
Conference ID: 5617240

Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit http://www.gracellbio.com/. Follow @GracellBio on LinkedIn.

Media contacts
Marvin Tang
marvin.tang@gracellbio.com

Kyle Evans
kyle.evans@westwicke.com

Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-report-fourth-quarter-2022-financials-on-monday-march-13-2023-301756161.html

SOURCE Gracell Biotechnologies Inc.

FAQ

When will Gracell Biotechnologies report its Q4 2022 financial results?

Gracell Biotechnologies plans to report its Q4 2022 financial results on March 13, 2023.

What time is the Gracell conference call on March 13, 2023?

The Gracell conference call is scheduled for 8:00 a.m. ET on March 13, 2023.

How can I join the Gracell Biotechnologies conference call?

You can join the Gracell conference call by dialing (800) 715-9871 for domestic or (646) 307-1963 for international calls, using conference ID 5617240.

Will there be a replay of the Gracell conference call?

Yes, a replay of the Gracell conference call will be available on their investor relations webpage shortly after the event.

What is the purpose of Gracell's upcoming financial results announcement?

The announcement aims to provide unaudited financial results and updates on recent developments in Gracell's operations.